Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:47 p.m. and Nov. 22, 2024, 7:47 p.m. from: Fierce Pharma.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer

Document Date: Nov. 20, 2024, 3:13 p.m. / Source: Fierce Pharma
Activity Class: CorporateFinanceActivity / Type: Acquisition / Region: Kingdom of Spain
Buyer: Target: Document Extract: With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar take over bid, it's likely back to the drawing board for Canadian private equity outfit Brookfield.
Document Source: https://www.fiercepharma.com/pharma/plasma-specialist-grifols-shrugs-private-equity-firm-brookfields-potential-eu65b-takeover (archive.org page / archive.org listing)


Exact Sciences ramps up colon cancer outreach to Hispanic community with Carlos Ponce partnership

Document Date: Nov. 19, 2024, 3:45 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Ponce, who hails from Puerto Rico, has starred in telenovelas like "Santa Diabla" and "Perro Amor ," among many others, as well as English-language films and TV shows including "Spy ," "Couples Retreat" and "7th Heaven ." According to Exact's announcement this week, the partnership with Ponce will include personal stories related to colon cancer and educational content in both English and Spanish about the importance of regular screening, including with Exact's own Cologuard at-home test. " As Latinos, sometimes we do n't like to talk about health topics-partially because we want to be strong, proud, and not worry or burden our families-and I think this is particularly the case for us as Latino men ," Ponce said in the announcement. " I 've learned over the past few years that it's our responsibility to talk about health issues with our loved ones ," he continued. " Knowledge is power, and knowing about available testing options for colon cancer is one of the best ways to make sure we 're present in our families' lives-now and in the future ."
Document Source: https://www.fiercepharma.com/marketing/exact-sciences-ramps-colon-cancer-outreach-hispanic-community-carlos-ponce-partnership (archive.org page / archive.org listing)


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030. The company followed up that reveal with news of a $ 1.2 billion contract with another anonymous, Asia - based pharmaceutical company in October. The latter deal is set to last through December 2037. Prior to those agreements, Samsung Bio expanded a long-running partnership with Belgium's UCB to manufacture an anti-tau candidate in progressive supranuclear palsy and retooled a deal with Baxter Healthcare to provide unspecified production services through 2034. While many other CDMOs have struggled to come to grips with the post-pandemic contracting industry, Samsung Bio has largely avoided headwinds since rising to prominence several years ago.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Rather than commenting on the latest production tie-up directly, the company's CEO, John Rim, pledged in a statement to continue pouring the proceeds from Samsung Bio's contracting projects back into the CDMO's production capabilities. Following a slate of high-value deals this year, Samsung Biologics is now partnered with 17 of the world's top 20 pharmaceutical companies, the manufacturer said in a release. Next up, the CDMO is adding antibody-drug conjugate services, including process development and conjugation, to its portfolio of offerings, Samsung Bio said. Samsung Biologics has been in the habit of disclosing high-dollar contracts with unnamed customers in recent months. Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Samsung Biologics has been in the habit of disclosing high-dollar contracts with unnamed customers in recent months. Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030. The company followed up that reveal with news of a $ 1.2 billion contract with another anonymous, Asia - based pharmaceutical company in October. The latter deal is set to last through December 2037. Prior to those agreements, Samsung Bio expanded a long-running partnership with Belgium's UCB to manufacture an anti-tau candidate in progressive supranuclear palsy and retooled a deal with Baxter Healthcare to provide unspecified production services through 2034.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)


PCI and ChiRhoClin partner to prevent shortage of pancreatic diagnostic drug

Document Date: Nov. 20, 2024, 2:30 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: PCI and ChiRhoClin partner to prevent shortage of pancreatic diagnostic drug. PCI Pharma Services, a CDMO, and the biotech ChiRhoClin inked a collaboration deal to address the potential shortage of a critical diagnostic drug used in testing for pancreatic disease and cancer. ChirRhoClin's ChiRhoStim drug is used for diagnosing pancreatic cancer and exocrine dysfunction, supports pancreatic function testing, assists with endoscopic retrograde cholangiopancreatography cannulation (which uses an endoscope and X-rays to examine and treat the liver, gallbladder, pancreas and bile ducts) and aids in collecting pancreatic fluid for diagnostic purposes. The drug has seen unusually high demand, and the company said in a Nov. 19 press release that it is working with the FDA's drug shortage team to gain approval for the commercial release of the first process performance qualification (PPQ) batch. This batch was produced at PCI's Bedford, New Hampshire, facility and packaged at the company's Philadelphia site.
Document Source: https://www.fiercepharma.com/manufacturing/pci-and-chirhoclin-partner-prevent-shortage-pancreatic-diagnostic-drug (archive.org page / archive.org listing)


Ideaya hires Gilead leader to head up commercialization push

Document Date: Nov. 19, 2024, 3:34 p.m. / Source: Fierce Pharma
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive who played a role in the commercialization of Trodelvy and Opdivo.
Document Source: https://www.fiercepharma.com/marketing/ideaya-hires-gilead-leader-head-commercialization-push (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.